1324-P: Screening for MASLD Using a Novel Point-of-Care Device, the Hepatoscope, in Diabetology
Authors: CAUSSY CYRIELLE , VERGÈS BRUNO , SEGRESTIN BERENICE , ROULAND ALEXIA , PETIT JEAN-MICHEL , DELAUNAY DOMINIQUE , CHARRIÈRE SYBIL , MOULIN PHILIPPE , DISSE EMMANUEL 
Published: June 2024

Introduction & Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly associated with type 2 diabetes (T2D) and the screening for MASLD and liver fibrosis is currently recommended. We evaluated the correlation of liver fibrosis and steatosis parameters between a FibroScan® and a new ultrasound imaging point-of-care device: Hepatoscope™.
Methods: This is an interim analysis including the subgroup of participants with T2D and MASLD age 40-80 years, BMI &lt;40 kg/m2 enrolled in an ancillary study of a prospective multicenter study in 3 diabetes clinics in France between Dec 2022 and Dec 2023 (NCT04435054). All participants underwent the same day liver stiffness measurement using vibration controlled transient elastography (VCTE) by FibroScan®, 2D-measurements of shear wave speed (2DTE) by Hepatoscope™, hepatic fat content assessment using controlled attenuation parameter (CAP) by FibroScan® and ultrasound attenuation (ATT) and backscattering coefficient (BSC) by Hepatoscope. The non-parametric spearman correlation coefficients between VCTE and 2DTE, and between CAP and ATT or BSC were assessed in participants with both valid VCTE and 2DTE.
Results: 130 participants (86% male) were included (mean age: 62.6 years, mean BMI: 31.7±3.7 kg/m2). Median liver parameters were as follows: VCTE: 6.5 ± 4.3 kPa, 2DTE: 6.2 ± 4.5 kPa, CAP: 313 ± 54 dB/m, ATT: 277 ±49 dB/m and BSC: -22.7±-5.3. 2DTE correlated strongly with VCTE (r2: 0.47, p&lt;0,001). Likewise, ATT and BSC using Hepatoscope™ correlated significantly with CAP (r2: 0.54, p&lt;0.001 and r2:0.61 p&lt;0.001, respectively).
Conclusion: These preliminary data indicate that Hepatoscope™ 2DTE is significantly correlated with VCTE. It provides the proof of concept that liver assessment using the Hepatoscope™ could be used in diabetology for liver fibrosis and steatosis assessment. Further studies in larger cohort are needed to determine the cut-offs and diagnostic performance of the Hepatoscope™ in diabetology.

Disclosure
C. Caussy: Other Relationship; Echosens, E-scopics, Novo Nordisk. Consultant; Lilly Diabetes. Other Relationship; Gilead Sciences, Inc. Consultant; GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp. Advisory Panel; Corcept Therapeutics. B. Vergès: Consultant; Lilly Diabetes, Novo Nordisk A/S. Advisory Panel; Recordati. Consultant; AstraZeneca, Sanofi. B. Segrestin: None. A. Rouland: Other Relationship; Lilly Diabetes, Sanofi, Novo Nordisk. J. Petit: None. D. Delaunay: None. S. Charrière: Other Relationship; Novo Nordisk, Lilly Diabetes. Consultant; biomarin. Other Relationship; Amgen Inc., Novartis AG, Amarin Corporation. P. Moulin: Other Relationship; Novo Nordisk, Ionis Pharmaceuticals, Sanofi. Advisory Panel; ulktragenix. E. Disse: Board Member; Novo Nordisk. Consultant; Novo Nordisk, Lilly Diabetes, Sanofi, Rhythm Pharmaceuticals, Inc., Johnson & Johnson Medical Devices Companies.

Funding
E-scopics